The cost of prematurity, accounted for in both human currency and financial dollars, has fueled decades of research committed to developing models with the ability to predict preterm birth (PTB). The goal of these models is either to improve outcomes for preterm infants through optimizing care or to reduce the PTB rate itself. This field of research has generated contributions to our understanding of the mechanisms responsible for preterm labor and even a few clinical achievements: progesterone to prevent recurrent PTB, antenatal corticosteroids (ACS) to improve a host of neonatal outcomes and cerclage in patients with multiple prior losses consistent with cervical insufficiency.
A more strict definition of optimal ACS timing (2-7 days) reduced this percentage to 19%. Overall, less than 50% of patients who delivered <34 weeks gestation received ACS in the optimal treatment window and more than one-third of patients receiving ACS delivered after 37 weeks gestation. We should be able to do better. Even a 'poor' model with a predictive accuracy of 50% would double the percentage of fetuses exposed to ACS within optimal timing and this would lead to significant improvements in neonatal outcomes without affecting the PTB rate at all.
Hence, with the focus not on reduction in PTB, but on developing an improved prediction model, we identify three focus areas for prematurity research and discuss each briefly: (1) differentiating early from late PTB, (2) etiology-specific approaches to prediction and (3) time-from-delivery analysis.
(1) Differentiating early from late PTB: Prediction of PTB should be dichotomized into the prediction of two separate events -early PTB before 34 weeks gestation and late PTB (34-37 weeks gestation). Early PTB represents 3.6% of US births, but accounts for the majority of neonatal mortality. 8 Despite overwhelming data that at least 80% of early PTB is caused by infection of the choriodecidua and amniotic cavity, 9,10 the genetic contributions and protein pathways resulting in early PTB have not been well characterized. On the contrary, PTB >34 weeks gestation is rarely associated with infection or inflammation, and the distribution of late PTB and post-term pregnancy are tails of a normal distribution, suggesting that these two entities are extremes of a normal physiological process. These two entities should be thought of as different pathological conditions; one prediction model will not work for both.
(2) Etiology-specific approaches to prediction: Within this framework, the work published by Ruiz et al. may represent a significant step in the right direction. A model to predict infectionmediated PTB will be useful in predicting early PTB and, in the absence of a clear understanding of other causes of early PTB, is the most viable approach for research. A follow-up study examining how IL-1ra, IL-10 and other cytokines (TNFa, MMP-9 and IL-6) can be utilized to predict infection-mediated PTB may have immediate clinical benefits. Although treatment of infectionmediated PTB may be an achievable long-term goal, ACS administration has already been shown to reduce mortality, neurologic handicap and chronic lung disease by 50 to 70% in premature infants born before 34 weeks gestation, 2, 11 even in the setting of intra-amniotic infection and inflammation. 12 As our understanding of how other pathological pathways may result in PTB increases, a long-term goal of research should be to develop a multi-analyte tool not only to predict PTB but also to identify the specific etiology involved, which may lead to more effective efforts to reduce the overall PTB rate. (3) Time-from-delivery analysis: As a final comment, we point out that, historically, scientists have understood that gene expression varies across different gestational age windows, and that predictive tests function optimally by restricting prediction to a narrow gestational age window. Successful examples of this approach include the maternal marker test (commonly called the sequential screen or quadruple screen), which can predict Down syndrome and Edwards syndrome in pregnancy by analysis of maternal blood. The quadruple screen, for instance, works well within a narrow gestational age window of 16-20 weeks, and normal protein levels vary by each week of gestation. Diagnosis of ectopic pregnancy, gestational trophoblastic cancers and even a simple urine pregnancy test are other successful examples of this fundamental doctrine of medical prediction during pregnancy. This same methodology has been applied to predicting PTB, but with extremely poor results. The review by Menon 6 cited previously concludes that none of the published biomarkers to date have the predictive accuracy necessary to be recommended for clinical practice.
Prediction of PTB differs from detection of Down syndrome or ectopic pregnancies. These conditions are uniformly present during the entire length of gestation. Simply put, embryos don't develop from a normal karyotype to Down syndrome and pregnancies don't convert from intra-uterine implantation to ectopic implantation. On the contrary, we hypothesize that early PTB is caused by an infection that occurs after normal pregnancy implantation and is highly variable in timing. It is likely that prediction of early PTB by a standard approach (comparison of protein levels at distinct gestational ages) is not achievable. Not all patients who deliver at 30 weeks gestation will have early infection at 20, 24 or 28 weeks, so protein analysis at those gestational ages will always suffer from that limitation. An alternate approach would be to analyze biological specimens classified in relation to time from actual delivery. For example, if a patient delivers at 29 0/7 weeks gestation, a sample taken at 28 0/7 weeks gestation could be classified as 't-7' and grouped with other 't-7' samples for composite analysis. A comparative analysis of samples taken between 't-2' and 't-7' may display quantitative protein differences that are not evident among samples taken between 20-22 weeks gestation to predict a birth that occurs either 40 or 100 days later. This type of analysis could be performed using bio-libraries already in existence.
Although accurate prediction of PTB has remained elusive for decades, we feel that the following three areas of focus are useful: (1) differentiating early from late PTB, (2) etiology-specific approaches to prediction and (3) appropriate analysis timing of samples. Hopefully, with these and other insights into PTB, the current decade will be the one in which accurate prediction of PTB becomes clinically available.
